6 Best Peptides for Pulmonary Fibrosis

What to Know Before Choosing a Peptide for Pulmonary Fibrosis

Pulmonary fibrosis is one of the harder frontiers in peptide research. The condition involves the progressive scarring of lung tissue, driven largely by a signaling protein called TGF-beta that pushes lung cells toward producing excess collagen rather than healthy tissue. The damage accumulates, lung function declines, and the two major approved non-peptide drugs slow that progression without reversing it. That gap is exactly what researchers and, increasingly, people living with the condition are looking to peptides to address.

Every compound in this guide earned its place by the same test: people use it or are actively discussing using it for pulmonary fibrosis, whether in clinical trial settings, in practitioner protocols, or in community research channels. That criterion does not require FDA approval, a completed randomized controlled trial, or even a published human study. Some compounds here have genuine clinical trial data. Others have strong preclinical evidence with no human trial data at all. A small number belong to a traditional research category with theoretical lung targeting but limited published fibrosis-specific evidence. Evidence strength is described honestly inside each entry and is never used as a filter for whether a compound belongs on this list.

The numbers in front of each entry reflect how prominently each compound appears across the published research and documented real-world use for this condition. They are not a verdict on which compound is best for any particular person. That judgment depends on health history, goals, and what someone builds out with their own protocol, which is the work the app is designed to support.

1. LTI-03: The Most Clinically Advanced Peptide in Trials

LTI-03 is a seven-amino-acid synthetic peptide derived from the scaffolding domain of a protein called Caveolin-1. Developed by Rein Therapeutics and previously known in the research literature as CSP7, it is the most clinically advanced peptide candidate for idiopathic pulmonary fibrosis currently in human trials.

What sets LTI-03 apart mechanistically is its breadth. Rather than targeting one pathway, it broadly attenuates what researchers call the idiopathic pulmonary fibrosis signaling pathway, a convergent set of signals involving TGF-beta, VEGFA, PDGFB, EGF, and FGF2. These are the growth factor receptors that become aberrantly active in IPF, driving the fibrotic cascade forward. LTI-03 also promotes the survival of type 2 alveolar epithelial cells, the lung cells whose loss is understood to be one of the initiating events in IPF pathology. Think of those cells as the first domino in the fibrotic sequence: when they die, the scarring program begins. Protecting them interrupts that sequence earlier than most approaches.

The clinical evidence is the strongest available for any peptide in this space. A completed Phase 1b safety trial in actual IPF patients showed positive trends in seven of eight biomarkers, with four reaching statistical significance. In ex vivo work using lung tissue slices from twelve patients with end-stage IPF, LTI-03 reversed fibrotic markers and promoted alveolar epithelial cell survival without causing cellular necrosis. A Phase 2 trial called RENEW is now actively enrolling patients across roughly fifty sites in the United States, United Kingdom, Germany, Poland, and Australia. The FDA lifted a previous clinical hold and cleared U.S. trials to resume.

LTI-03 is not available outside of clinical trials and cannot be obtained through a telemedicine platform or a research chemical supplier. For anyone with IPF who wants to consider it, the path is inquiring about enrollment in the RENEW trial. That is a real limitation for a guide like this one, but understanding where the leading edge of peptide science for this condition actually sits is part of understanding the full landscape.

2. GHK-Cu: The Most-Studied Self-Administered Candidate

GHK-Cu is a tripeptide that occurs naturally in human plasma, formed from glycine, histidine, and lysine, complexed with copper. It is found at meaningful concentrations in youth and declines substantially with age. Within the pulmonary fibrosis research space it has accumulated the most compelling preclinical evidence of any self-administered peptide.

Its mechanism in the context of lung fibrosis runs along several parallel tracks. It directly inhibits TGF-beta and Smad signaling, the central driver of fibroblast activation and collagen overproduction in IPF. Smad proteins act as messenger molecules that carry the TGF-beta signal into the cell nucleus and switch on genes responsible for scar tissue formation; GHK-Cu interferes with that process upstream. It also decreases IGF-1 expression, another growth signal implicated in fibrotic proliferation, and carries strong antioxidant properties that counteract the oxidative damage amplifying fibrotic signaling in diseased lung tissue.

One property that draws particular attention in the research literature is what some investigators describe as gene expression resetting, an apparent ability to shift the activity profile of aged or damaged tissue toward a pattern resembling healthier tissue. That has been observed in work with human lung tissue models, not only in animal models, placing GHK-Cu in a relatively rare category among self-administered peptides: it has both bleomycin-model animal data and ex vivo human IPF lung tissue data. No randomized controlled trial in living IPF patients exists as of 2026, and that gap matters. But the combination of a mechanistically relevant pathway, animal evidence, and human tissue data makes GHK-Cu one of the more grounded compounds in the community-use conversation around pulmonary fibrosis.

It is available as a research chemical and in some topical cosmetic formulations. People pursuing it for lung health are doing so based on the preclinical and ex vivo data, with full awareness that the step from laboratory findings to confirmed human efficacy has not yet been taken.

3. TB-500: For Tissue Repair and Anti-Fibrotic Signaling

TB-500 is a synthetic peptide derived from the active region of a naturally occurring protein called Thymosin Beta-4. The specific sequence is the actin-binding domain of that protein, seven amino acids that carry most of Thymosin Beta-4's biological activity relevant to tissue repair and cell signaling. It is one of the most widely used research peptides in the biohacking and self-administration community, primarily associated with injury recovery, and it has drawn meaningful attention in the pulmonary fibrosis space because of how directly its mechanisms intersect with the fibrotic process.

The mechanism most relevant to fibrosis involves actin sequestration. TB-500 binds to actin monomers, the individual protein units that cells use to reorganize their internal scaffolding when they change shape. One of the key steps in fibrosis is the transformation of ordinary fibroblasts into myofibroblasts, the scar-forming cells that produce excess collagen. That transformation requires cytoskeletal reorganization, and TB-500's actin binding directly interferes with it. TB-500 also works through the TGF-beta pathway to reverse epithelial-mesenchymal transition, the process by which lung epithelial cells take on fibroblast-like characteristics and contribute to scarring. It further modulates AKT signaling, a cellular survival and proliferation pathway, to reduce myofibroblast activity more broadly. In bleomycin-induced mouse models of pulmonary fibrosis, the standard preclinical test for this condition, TB-500 has shown measurable antifibrotic effects, and it appears to support the regeneration of alveolar epithelial cells and club cells important for lung repair.

No clinical trial has tested TB-500 specifically for pulmonary fibrosis as of 2026. The preclinical data is substantive, but the leap from bleomycin-induced mouse fibrosis to human IPF is a large one. Community discussion around anti-fibrotic peptides mentions TB-500 alongside GHK-Cu as compounds people are exploring, but the general framing is cautious: the mechanism supports the possibility, the controlled data does not yet confirm it. TB-500 is available as a research chemical. It is also on the World Anti-Doping Agency prohibited list as an analog of Thymosin Beta-4, which is relevant for anyone subject to competitive sports testing.

4. BPC-157: For Fibroblast Activity and Collagen Remodeling

BPC-157, Body Protection Compound-157, is a fifteen-amino-acid synthetic peptide derived from a protein found in gastric juice. It is one of the most broadly discussed compounds in the research peptide community, primarily for gut, tendon, and muscle repair, and it has a specific mechanistic rationale for pulmonary fibrosis worth understanding on its own terms.

In the fibrosis context, BPC-157 operates largely by reducing the expression of TGF-beta 1, the signaling protein that drives the fibrotic cascade, and by decreasing the expression of alpha-smooth muscle actin, the molecular marker distinguishing myofibroblasts from ordinary fibroblasts. Myofibroblasts are the scar-forming cells at the center of IPF pathology; reducing their activity or steering fibroblasts away from that fate is the goal of most anti-fibrotic approaches. BPC-157 also modulates the ratio between MMP-1 and TIMP-1, two proteins that govern whether collagen in the extracellular matrix is broken down or accumulates. Shifting that ratio toward MMP-1 activity means favoring collagen turnover over collagen buildup, which is the direction fibrosis needs to move.

The evidence base is preclinical. Animal models have shown these effects, and BPC-157 is mechanistically plausible in the community-use conversation around fibrosis. No human clinical trial for pulmonary fibrosis exists as of 2026. A researcher who spent four months investigating BPC-157 broadly concluded the most honest answer to questions about efficacy is that we do not know, citing the absence of randomized controlled trials and the confounding effects of placebo, online enthusiasm, and commercial incentives. That assessment applies here. The mechanistic rationale is real. The human evidence is absent. Some users report side effects including anxiety and anhedonia. BPC-157 is classified as a research chemical and is not FDA-approved for any therapeutic use.

5. Chonluten: The Lung-Targeted Bioregulator

Chonluten is a short tripeptide, three amino acids in the sequence lysine-glutamic acid-aspartic acid, developed within the Russian peptide bioregulator research tradition associated with Vladimir Khavinson and colleagues. Peptide bioregulators in this framework are characterized by their claimed tissue specificity, and Chonluten is specifically positioned as a bronchial and lung tissue peptide intended to support the function of bronchial epithelial cells.

The proposed mechanism belongs to the category of gene regulatory activity that Khavinson's group describes for peptide bioregulators: the peptide is said to penetrate cell nuclei and interact with DNA to influence gene expression in its target tissue. In bronchial and lung tissue, this is described as supporting the restoration and functional integrity of the epithelial cells lining the airways. Whether and how that mechanism applies to the fibrotic process specifically is not established in the peer-reviewed literature covering IPF peptide pipelines. Chonluten does not appear in the major English-language reviews of anti-fibrotic peptide candidates, and no indexed clinical trial for pulmonary fibrosis has been identified as of 2026.

It is included here because it is one of the compounds people in the bioregulator research community actively use and discuss for lung health, and the inclusion criterion for this guide is use and discussion, not evidence depth. People who use Chonluten for lung conditions are typically doing so based on the tissue-targeting rationale and the broader Khavinson framework, alongside personal or community-reported experience. That context belongs in an honest account of this landscape, with the evidence gap stated as plainly as it is here. Chonluten is available primarily through suppliers specializing in Russian peptide bioregulators, typically as an oral supplement or sublingual preparation. It is not FDA-approved for any indication and is not used in mainstream Western clinical practice.

6. Taxorest: The Thymic Bioregulator With an Immune Rationale

Taxorest is another peptide bioregulator from the Khavinson research tradition, this one derived from the thymus gland. The thymus trains and produces T-cells, the immune cells that coordinate adaptive immune responses, and Taxorest is positioned as a thymus-targeting peptide intended to support immune regulation with proposed effects on T-cell activity and broader immune homeostasis.

The connection to pulmonary fibrosis is indirect but not implausible. IPF has a meaningful immune component: dysregulated immune activity contributes to the inflammatory environment that precedes and accompanies fibrotic deposition, and abnormal T-cell populations have been observed in IPF patients. A compound that modulates thymic output and T-cell regulation could theoretically reduce the immune-driven component of the fibrotic process. That is the theoretical basis that leads some practitioners and users in the bioregulator community to consider Taxorest alongside lung-targeted peptides like Chonluten for respiratory conditions.

The honest accounting of the evidence: no clinical trial data for pulmonary fibrosis has been identified as of 2026, and Taxorest does not appear in the mainstream IPF peptide pipeline literature. Its evidence base sits within the Khavinson research tradition, which is a distinct framework from the indexed randomized controlled trial pathway that Western regulatory agencies use to evaluate therapeutic compounds. Community discussion specifically about Taxorest for IPF is sparse compared with compounds like TB-500 or BPC-157. It is included here because it is an actively used compound in the bioregulator space and because people exploring the full landscape of peptide options for respiratory health will encounter it. That encounter deserves an honest account rather than a silent omission. Taxorest is available from specialty suppliers focused on Russian peptide bioregulators. It is not FDA-approved for any indication.

How These Peptides Compare

Frequently Asked Questions

Are any peptides FDA-approved for pulmonary fibrosis?

No peptide is currently FDA-approved for pulmonary fibrosis. The approved drugs for IPF, nintedanib, pirfenidone, and the recently approved nerandomilast, are small molecules, not peptides. The most clinically advanced peptide in this space, LTI-03, is in Phase 2 trials but has not completed that process, and no peptide has yet demonstrated efficacy in a full randomized controlled trial in IPF patients.

Can I access any of these peptides outside a clinical trial?

Most of them, yes, with the important exception of LTI-03, which is only accessible through enrollment in the RENEW trial. GHK-Cu, TB-500, BPC-157, Chonluten, and Taxorest are available through research chemical suppliers or specialty bioregulator sources, though none are approved for human therapeutic use for pulmonary fibrosis and purchasing them for that purpose carries regulatory risk. Some people explore these compounds through functional medicine practitioners who work with research peptides off-label.

How strong is the evidence that peptides help with pulmonary fibrosis?

It varies considerably by compound. LTI-03 has Phase 1b human data and ex vivo evidence from actual IPF patient tissue, the strongest available for any peptide here. GHK-Cu has animal model data and ex vivo human lung tissue data. TB-500 and BPC-157 have preclinical animal model evidence. Chonluten and Taxorest have neither indexed preclinical fibrosis data nor clinical trial data, and are used based on their tissue-targeting and immune-regulation rationale within the bioregulator tradition. Across the whole field, no compound has demonstrated efficacy in a completed randomized controlled trial in living IPF patients.

Why do people use peptides for pulmonary fibrosis when the evidence is still early?

The approved standard-of-care drugs slow progression but do not reverse fibrosis, and roughly one in five patients stops them due to side effects. For people facing a progressive condition with limited options, the mechanistic rationale behind compounds like GHK-Cu and TB-500 is genuinely compelling even without human trial data. Many people using these compounds are aware of the evidence gap and frame their use as informed experimentation while monitoring their lung function closely with their treating physician.

Does the WADA prohibition on TB-500 matter for pulmonary fibrosis patients?

For most people managing IPF, no. The World Anti-Doping Agency prohibited list applies to competitive athletes subject to testing, and the typical person with pulmonary fibrosis is not in that category. TB-500 and Thymosin Beta-4 are on the WADA list, which is worth knowing for anyone who is both a competitive athlete and researching these compounds, but it carries no practical consequence for the broader population living with this condition.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for pulmonary fibrosis in one place.